Mineralys Therapeutics (MLYS) Accumulated Expenses (2022 - 2026)

Mineralys Therapeutics has disclosed Accumulated Expenses across 5 years of filings, most recently posting $13.6 million for Q1 2026.

• Accumulated Expenses for Q1 2026 came in at $13.6 million, up 4.53% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.6 million (up 4.53% YoY), and the FY2025 annual result was $13.1 million, down 7.56% from the prior year.
• Accumulated Expenses came in at $13.6 million for Q1 2026 at Mineralys Therapeutics, up from $13.1 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $28.2 million in Q3 2024 to a low of $4.0 million in Q2 2023.
• The 5-year median for Accumulated Expenses is $13.3 million (2025), against an average of $14.4 million.
• Across the five-year window, Accumulated Expenses surged 565.42% in 2024 and retreated 28.78% in 2025, its largest moves.
• Mineralys Therapeutics' Accumulated Expenses stood at $6.2 million in 2022, then jumped by 60.41% to $9.9 million in 2023, then soared by 43.38% to $14.2 million in 2024, then retreated by 7.56% to $13.1 million in 2025, then grew by 3.86% to $13.6 million in 2026.
• The last three Accumulated Expenses figures came in at $13.6 million (Q1 2026), $13.1 million (Q4 2025), and $22.4 million (Q3 2025), per Business Quant data.